Hepatitis B treatment is in the experimentation stage expecting to obtain more effective and less resistant treatments. Most treatments under experimentation are nucleoside and nucleotide analogues that competitively inhibit HBV polymerase. Emtricitabine is a drug that could be used in con-infected HIV patients with the inconvenience of cross-resistance to lamivudine. Tenofovir is a promising drug for co-infected HIV patients, not only for the HbeAg negative but also for those resistant to lamuvidine. Pro-drugs such as pradefovir are considered more effective and with less adverse effects than the original drug. Most of these drugs require more studies to define its role in the treatment of chronic hepatitis B.

tenofovir; emtricitabine; pradefovir